lilly glp-1 drug Eli Lilly's New $299 Month-Long GLP‑1 Injector Shows Why It's Winning the Weight‑Loss Race Lilly to pour $6.5 billion

The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.

The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).

GLP-1 medications are becoming one of the most important workplace health and benefits topics

Glycemic monitoring with CGMs, glucose-lowering agents (GLP-1 receptor agonists), innovative insulin delivery systems, and mental health check-ins are just a few updates to the ADA 2025 Standards of Care.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for diabetes and obesity, exhibit pleiotropic effectsincluding anti-inflammatory, ...

Scientists were chasing an incretin hormone, and when GLP-1 was finally discovered, we found that it had a pronounced satiety effect, slowed down gastric emptying, and actually reduced postprandial insulin response